{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:12:11Z","timestamp":1768435931900,"version":"3.49.0"},"reference-count":20,"publisher":"FapUNIFESP (SciELO)","issue":"11","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"DOI":"10.1590\/1806-9282.20230789","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:14:46Z","timestamp":1698405286000},"source":"Crossref","is-referenced-by-count":5,"title":["Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats"],"prefix":"10.1590","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4200-2659","authenticated-orcid":false,"given":"\u00c7a\u011flayan","family":"Ate\u015f","sequence":"first","affiliation":[{"name":"University of Health Sciences,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1137-8650","authenticated-orcid":false,"given":"Berna","family":"Dilbaz","sequence":"additional","affiliation":[{"name":"University of Health Sciences,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7017-8854","authenticated-orcid":false,"given":"Seval Y\u0131lmaz","family":"Ergani","sequence":"additional","affiliation":[{"name":"University of Health Sciences,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2609-3490","authenticated-orcid":false,"given":"Fuad","family":"Atabay","sequence":"additional","affiliation":[{"name":"University of Health Sciences,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2023]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00404-020-05855-1","article-title":"Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model","volume":"303","author":"Hortu I","year":"2021","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3906\/sag-2005-297","article-title":"Transient receptor potential melastatin 2 ion channel activity in ovarian hyperstimulation syndrome physiopathology","volume":"51","author":"\u015eanl\u0131 C","year":"2021","journal-title":"Turk J Med Sci"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1757-2215-7-54","article-title":"Polymorphisms of VEGF and VEGF receptors are associated with the occurrence of ovarian hyperstimulation syndrome (OHSS)-a retrospective case-control study","volume":"7","author":"Nouri K","year":"2014","journal-title":"J Ovarian Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/DDDT.S351292","article-title":"Nintedanib treatment after ovulation is an effective therapeutic strategy for the alleviation of ovarian hyperstimulation syndrome (OHSS) in a mouse model","volume":"16","author":"Jiang S","year":"2022","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/01443615.2020.1870944","article-title":"Cabergoline versus calcium infusion in the prevention of ovarian hyperstimulation syndrome: a randomised controlled study","volume":"42","author":"Fouda UM","year":"2022","journal-title":"J Obstet Gynaecol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12958-015-0102-4","article-title":"Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells","volume":"13","author":"Ferrero H","year":"2015","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40123-021-00354-1","article-title":"A review of aflibercept treatment for macular disease","volume":"10","author":"Anguita R","year":"2021","journal-title":"Ophthalmol Ther"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.tranon.2019.04.019","article-title":"Two-week aflibercept or erlotinib administration does not induce changes in intestinal morphology in male Sprague-Dawley rats but aflibercept affects serum and urine metabolic profiles","volume":"12","author":"Forsg\u00e5rd RA","year":"2019","journal-title":"Transl Oncol"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/09513590.2022.2034147","article-title":"Ginkgo biloba extract 761 reduces vascular permeability of the ovary and improves the symptom of ovarian hyperstimulation syndrome in a rat model","volume":"38","author":"Zhang J","year":"2022","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/14647273.2017.1331048","article-title":"Outpatient management of severe ovarian hyperstimulation syndrome: a systematic review and a review of existing guidelines","volume":"21","author":"Gebril A","year":"2018","journal-title":"Hum Fertil (Camb)"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002414R","article-title":"The systemic antiangiogenic effect of intravitreal aflibercept injection in a mouse model of retinopathy of prematurity","volume":"35","author":"Ichiyama Y","year":"2021","journal-title":"FASEB J"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1080\/09513590.2021.1942453","article-title":"sRAGE downregulates the VEGF expression in OHSS ovarian granulosa cells","volume":"37","author":"Wang B","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"ref13","first-page":"1761","article-title":"Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study","volume":"9","author":"Pala \u015e","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/REP-17-0268","article-title":"Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion","volume":"154","author":"Zhai J","year":"2017","journal-title":"Reproduction"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.repbio.2019.03.005","article-title":"Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): a potentially safer and more effective protocol","volume":"19","author":"Gaafar S","year":"2019","journal-title":"Reprod Biol"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial","volume":"139","author":"Brown DM","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa2204225","article-title":"Aflibercept monotherapy or bevacizumab first for diabetic macular edema","volume":"387","author":"Jhaveri CD","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3109\/09513590.2013.813470","article-title":"Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model","volume":"29","author":"Engin-Ustun Y","year":"2013","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1167\/iovs.17-22853","article-title":"Changes in blood pressure and urine albumin-creatinine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema","volume":"59","author":"Glassman AR","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ando.2020.12.008","article-title":"The risks of medical treatment of prolactinoma","volume":"82","author":"Castinetti F","year":"2021","journal-title":"Ann Endocrinol (Paris)"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0104-42302023001100616&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:14:59Z","timestamp":1698405299000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302023001100616&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023]]}},"alternative-id":["S0104-42302023001100616"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.20230789","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e20230789"}}